Dendrite Awarded Field Support Services Contract by Leading European Pharmaceutical Company
November 07 2006 - 3:00PM
Business Wire
Dendrite International, Inc., (NASDAQ: DRTE) a leading provider of
pharmaceutical industry solutions, today announced that the company
has signed a three-year field support services agreement with a
prominent European pharmaceutical company. Under the terms of the
agreement, Dendrite will provide premium help desk and hardware
services for the company�s French operation, which uses a
third-party based CRM solution. The operation will be staffed and
managed by an onsite Dendrite team based at the pharmaceutical
company�s local offices. �We�re confident that with our history of
successfully supporting premium field organizations � both on our
sales force effectiveness solutions as well as third-party systems,
this customer will have the tools needed to achieve higher
productivity returns,� said Mario Mauri, president of Dendrite
Europe. Dendrite�s premium field support services are designed to
enable higher field representative productivity for life science
companies around the world. These services are provided in the
local language, within local time zones and are available at the
customer location or as a syndicated service. About Dendrite
Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global,
pharmaceutical industry. The Company�s clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies. For more information, please visit www.dendrite.com.
Note: Dendrite is a registered trademark of Dendrite International,
Inc. This document may contain forward-looking statements that may
be identified by such forward-looking terminology as "expect,"
"believe," "anticipate," "will," "intend," "plan," "target,"
"outlook," "guidance," and similar statements or variations. Such
forward-looking statements are based on our current expectations,
estimates, assumptions and projections and involve significant
risks and uncertainties, including risks which may result from our
dependence on the pharmaceutical industry; fluctuations in
quarterly revenues due to lengthy sales and implementation cycles
for certain of our solutions; our fixed expenses in relation to
fluctuating revenues and variations in customers' budget cycles;
dependence on certain major customers; changes in demand for our
products and services attributable to any weakness experienced in
the economy or mergers, acquisitions and consolidations in the
pharmaceutical industry; successful and timely development and
introduction of new products and versions; rapid technological
changes; increased competition; international operations;
integrating the entities we acquire; our ability to effectively
manage our growth; the protection of our proprietary technology;
our ability to compete in the Internet-related products and
services market; the continued demand for Internet-related products
and services; the ability of our third party vendors to respond to
technological change; our ability to maintain our relationships
with third-party vendors; less favorable than anticipated results
from strategic relationships; dependence of data solutions on
strategic relationships; events which may affect the U.S. and world
economies; and catastrophic events which could negatively affect
our information technology infrastructure. Other important factors
that should be reviewed and carefully considered are included in
the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to
reflect actual results, changes in assumptions or other changes
affecting such forward-looking statements. Dendrite International,
Inc., (NASDAQ: DRTE) a leading provider of pharmaceutical industry
solutions, today announced that the company has signed a three-year
field support services agreement with a prominent European
pharmaceutical company. Under the terms of the agreement, Dendrite
will provide premium help desk and hardware services for the
company's French operation, which uses a third-party based CRM
solution. The operation will be staffed and managed by an onsite
Dendrite team based at the pharmaceutical company's local offices.
"We're confident that with our history of successfully supporting
premium field organizations -- both on our sales force
effectiveness solutions as well as third-party systems, this
customer will have the tools needed to achieve higher productivity
returns," said Mario Mauri, president of Dendrite Europe.
Dendrite's premium field support services are designed to enable
higher field representative productivity for life science companies
around the world. These services are provided in the local
language, within local time zones and are available at the customer
location or as a syndicated service. About Dendrite Founded in
1986, Dendrite International (NASDAQ: DRTE) enables sales,
marketing, clinical and compliance solutions for the global,
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies. For more information, please visit www.dendrite.com.
Note: Dendrite is a registered trademark of Dendrite International,
Inc. This document may contain forward-looking statements that may
be identified by such forward-looking terminology as "expect,"
"believe," "anticipate," "will," "intend," "plan," "target,"
"outlook," "guidance," and similar statements or variations. Such
forward-looking statements are based on our current expectations,
estimates, assumptions and projections and involve significant
risks and uncertainties, including risks which may result from our
dependence on the pharmaceutical industry; fluctuations in
quarterly revenues due to lengthy sales and implementation cycles
for certain of our solutions; our fixed expenses in relation to
fluctuating revenues and variations in customers' budget cycles;
dependence on certain major customers; changes in demand for our
products and services attributable to any weakness experienced in
the economy or mergers, acquisitions and consolidations in the
pharmaceutical industry; successful and timely development and
introduction of new products and versions; rapid technological
changes; increased competition; international operations;
integrating the entities we acquire; our ability to effectively
manage our growth; the protection of our proprietary technology;
our ability to compete in the Internet-related products and
services market; the continued demand for Internet-related products
and services; the ability of our third party vendors to respond to
technological change; our ability to maintain our relationships
with third-party vendors; less favorable than anticipated results
from strategic relationships; dependence of data solutions on
strategic relationships; events which may affect the U.S. and world
economies; and catastrophic events which could negatively affect
our information technology infrastructure. Other important factors
that should be reviewed and carefully considered are included in
the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to
reflect actual results, changes in assumptions or other changes
affecting such forward-looking statements.
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Aug 2023 to Aug 2024